Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;48(12):1444-1450.
doi: 10.1111/pace.70069. Epub 2025 Oct 23.

Trends and Outcomes of Anticoagulation for Post-Operative Atrial Fibrillation After Coronary Artery Bypass Graft

Daniel S Cheah  1 , Kathryn Tsai  1 , Krishna Prasad Kurpad  2 , Yousra Khalid  3 , Sanjay S Mehta  1   2
Affiliations

Trends and Outcomes of Anticoagulation for Post-Operative Atrial Fibrillation After Coronary Artery Bypass Graft

Daniel S Cheah et al. Pacing Clin Electrophysiol. 2025 Dec.

Abstract

Background: The benefit of oral anticoagulation (OAC) in patients with new-onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was previously left to the physician's discretion. The aim of this study is to identify the most effective anticoagulant regimens for reducing stroke rates in POAF patients after coronary artery bypass grafting (CABG).

Methods: Using the Epic Cosmos database, we included all US patients who underwent CABG without concomitant aortic/mitral valve replacement (MVR) from 2017 to 2023. Primary outcomes include demographics of POAF/non-POAF patients and complication rates among patients without anticoagulation, on direct oral anticoagulation (DOAC), or on warfarin.

Results: Of the 147,546 patients studied, 7.6% (11,336) developed POAF. At 60 days, the use of OAC for POAF was associated with a decrease in all-cause mortality without any difference in thromboembolism rates. At 12 months, there was no difference between all-cause mortality and thromboembolism rates between the OAC and the no anticoagulation (NA) cohorts.

Conclusions: The benefit of long-term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear, as there was no reduction in thromboembolic events with anticoagulation despite a reduction in all-cause mortality at 60 days. No significant reduction in thromboembolic events or all-cause mortality was exhibited at 1 year. Thus, the benefit of long-term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear.

Keywords: CABG; anticoagulation; atrial fibrillation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of included and excluded patients. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
(A) POAF incidence over the years; (B) Use of OAC for CABG patients over the years. [Colour figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Kosmidou I., Chen S., Kappetein A. P., et al., “New‐Onset Atrial Fibrillation After PCI or CABG for Left Main Disease,” Journal of the American College of Cardiology 71 (2018): 739–748. - PubMed
    1. January C. T., Wann L. S., Alpert J. S., et al., ACC/AHA Task Force Members , “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society,” Circulation 130 (2014): 2071–2104. - PubMed
    1. Taha A., Nielsen S. J., Bergfeldt L., et al., “New‐Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long‐Term Outcome: A Population‐Based Nationwide Study From the SWEDEHEART Registry,” Journal of the American Heart Association 10 (2021): e017966. - PMC - PubMed
    1. Chen A., Stecker E., and Warden B. A., “Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges,” Journal of the American Heart Association 9 (2020): e017559. - PMC - PubMed
    1. van de Kar M. R. D., van Brakel T. J., van't Veer M., et al., “Anticoagulation for Post‐Operative Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting: A Meta‐Analysis,” European Heart Journal (2024): ehae267. - PubMed